151
|
Man MQ, Wood L, Elias PM, Feingold KR. Cutaneous barrier repair and pathophysiology following barrier disruption in IL-1 and TNF type I receptor deficient mice. Exp Dermatol 2007. [DOI: 10.1111/j.1600-0625.1999.tb00380.x] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
|
152
|
Masci P, Olencki T, Wood L, Rybicki L, Jacobs B, Williams B, Faber P, Bukowski R, Tong K, Borden EC. Gene modulatory effects, pharmacokinetics, and clinical tolerance of interferon-alpha1b: a second member of the interferon-alpha family. Clin Pharmacol Ther 2007; 81:354-61. [PMID: 17339865 DOI: 10.1038/sj.clpt.6100081] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
Interferon-alpha1 (IFN-alpha1), which may have a primary role in innate immunity, differs significantly in amino-acid sequence from IFN-alpha2, the only recombinant IFN-alpha with substantial clinical evaluation. Patients with metastatic malignancies received daily subcutaneous doses of 1.5-270 mug/m(2) of recombinant IFN-alpha1b. Gene modulation, pharmacokinetics, tolerability, and disease response were determined. Significant (P<0.01) dose and gene-dependent increases of 2-10 fold occurred in IFN-stimulated genes, including four (tumor necrosis factor-related apoptosis-inducing ligand, cig 5, p56, GEM) never previously identified as increased in patients; significant increases (P<0.01) resulted at the lowest dose (1.5 microg/m(2); 1.5 x 10(4) human antiviral units/m(2)). Increases (P<0.01) were sustainable for >4 weeks. Peak levels of IFN-alpha1b were at 3 h; an increase of approximately eightfold in both C(max) and AUC occurred between 15 microg/m(2) and 270 microg/m(2). Chronic toxicities of anorexia, weight loss, and fatigue were relatively uncommon. Eighteen patients were treated for >8 weeks; none experienced >grade 1 weight loss. Three patients at the highest dose developed grade 3 fatigue after > or =3 months, which required dose reduction or discontinuation. Patient acceptability of fatigue defined a dose for initiation of Phase II trials, 270 microg/m(2). Six patients (five with renal cell carcinoma) had progression-free survival for >1 year, including two who had partial responses. IFN-alpha1b resulted in potent stimulation of IFN-regulated genes and tumor regressions in renal cell carcinoma. Unique gene modulatory effects, when coupled with the moderate severity of side effects and a potentially central role in innate immunity, provide rationale for further clinical evaluation of IFN-alpha1 in virus infections and cancer.
Collapse
|
153
|
Ray A, Wood L, Macula A, Pogozelski W. Detection Of Cross‐Hybridized DNA Strands within Pools Using SYBR Green I Fluorescence. FASEB J 2007. [DOI: 10.1096/fasebj.21.5.a266-d] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
154
|
Janle EM, Lila MA, Wood L, Higgins A, Yousef GG, Rogers RB, Kim H, Jackson G, Weaver CM. Kinetics and tissue distribution on 14C labeled grape polyphenol fractions. FASEB J 2007. [DOI: 10.1096/fasebj.21.6.a1070-a] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
|
155
|
Bishop M, Macula AJ, Nimmo K, Wood L, Pogozelski WK, Renz TE. Group testing to annihilate pairs applied to DNA cross-hybridization elimination using SYBR Green I. J Comput Biol 2007; 14:84-96. [PMID: 17381348 DOI: 10.1089/cmb.2006.0114] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
A group testing (or pooling) method for DNA strands that identifies at least one strand in a pair of cross-hybridized oligonucleotides is given. This pooling method can be extended to any population of objects where certain pairs together produce an observable function or signal. Pairs of objects may work together to produce an undesirable result or a detrimental function. If just a single element of such a pair is identified and eliminated, then the undesirable function of that pair is destroyed. In particular, the ability to ensure that a set DNA probes do not yield undesired cross-hybridizations is important when these probes and/or their complements are used in the production of a hybridization signal that is intended to convey information. Here we report a "proof of principle" method, similar to those used to screen DNA libraries, that screens pools of probes for unwanted cross-hybridization events and identifies the offending probes. In the reported experiment, a cross-hybridized duplex in a pool of probes is detected by using the fluorescent dye SYBR Green I. This dye is known to produce greater fluorescence when bound to duplex DNA as opposed to single-stranded DNA. The method described here is sensitive, fast, and simple.
Collapse
|
156
|
Miller L, Mattison P, Paul L, Wood L. The effects of transcutaneous electrical nerve stimulation (TENS) on spasticity in multiple sclerosis. Mult Scler 2007; 13:527-33. [PMID: 17463075 DOI: 10.1177/1352458506071509] [Citation(s) in RCA: 47] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Spasticity is a common and often disabling symptom associated with multiple sclerosis (MS). Transcutaneous electrical nerve stimulation (TENS) has been found effective in reducing spasticity in conditions such as stroke, but there is little evidence to support its use in MS. The aim of this study was to evaluate the effectiveness of TENS on spasticity in MS and, furthermore, to compare two different application times. Thirty-two subjects were randomized into two groups, and a single, blind, crossover design was used to compare two weeks of 60 minutes and 8 hours daily of TENS applications (100 Hz and 0.125 ms pulse width). Outcomes were examined using the Global Spasticity Score (GSS), the Penn Spasm Score (PSS), and a visual analogue scale (VAS) for pain. The results of the study demonstrated that there were no statistically significant differences in the GSS following either 60 minutes or 8 hours daily of TENS (P=0.433 and 0.217, respectively). The 8-hour application time led to a significant reduction in muscle spasm (P=0.038) and pain (P = 0.008). Thus, this study suggests that, whilst TENS does not appear to be effective in reducing spasticity, longer applications may be useful in treating MS patients with pain and muscle spasm. Multiple Sclerosis 2007; 13: 527-533. http://msj.sagepub.com
Collapse
|
157
|
Shaheen PE, Tamaskar IR, Salas RN, Rini BI, Garcia J, Wood L, Dreicer R, Bukowski RM. Thyroid function tests (TFTs) abnormalities in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sunitinib. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4605] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4605 Background: Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors. It has anti-tumor activity in mRCC pts with toxicity including fatigue. We investigated TFTs abnormalities and related signs and symptoms in pts with mRCC receiving sunitinib. Methods: The medical records of pts with mRCC enrolled in 4 ongoing clinical trials of sunitinib were reviewed. TFTs assessment (TSH, T3 and T4) was undertaken based on the clinical suspicion of treating physicians. Patient demographics, frequency and values of TFTs and any signs and symptoms of thyroid dysfunction were collected. Abnormal TFTs and treatment outcome were correlated. Results: Between 5/2004 and 12/2005, 62 pts (43 males, 19 females) were treated with sunitinib. The median age was 58 years (range, 23–72). Fifty-five pts had TFTs assessed while on treatment and 40 pts (65% of total) had one or more abnormality. Two pts had well-controlled hypothyroidism prior to initiation of sunitinib. TFTs abnormalities were consistent with hypothyroidism in all pts including one who initially developed transient hyperthyroidism. Signs and symptoms possibly related to hypothyroidism were found in 33 pts (53% of total) with abnormal TFTs and were initially attributed to sunitinib. Signs and symptoms included fatigue in 33 pts, anorexia in 20 pts, fluid retention in 17 pts, and skin/hair changes in 13 pts. Thyroid hormone replacement was undertaken in 12 pts and resulted in improvement of symptoms in 6 pts. Among the 40 pts with abnormal TFTs 29 pts had tumor evaluation; 13 had SD, 8 had PR, 2 had CR. There was no correlation between abnormal TFTs and treatment outcome. Conclusions: TFTs abnormalities are common in pts with mRCC treated with sunitinib. Thyroid hormone replacement is indicated in such pts to improve hypothyroidism-related symptoms and possibly to improve treatment tolerance. [Table: see text]
Collapse
|
158
|
Suppiah R, Finke J, Rini BI, Richmond A, Wood L, Elson P, Shaheen P, Garcia J, Dreicer R, Bukowski R. T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: Correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.2526] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
2526 Background: High numbers of regulatory T cells (Treg) and high expression of forkhead box transcription factor (FoxP3) in Treg are associated with decreased survival in various malignancies, likely via immunosuppression. Studies demonstrate Th1 suppression (IFN-γ) and Th2 (Il-4) promotion in metastatic renal cell carcinoma (mRCC) patients (pts). The aim of the present study was to determine the profile of Th1, Th2, and Treg at baseline and after 28 days of therapy with the multi-targeted tyrosine kinase inhibitor, sunitinib malate (SU11248). Further, correlation of changes in these parameters and tumor shrinkage (TS) was examined. Methods: Blood was obtained from cytokine-refractory, clear cell mRCC pts on day 1 (pre-treatment) and after 28 days of sunitinib 50mg daily. T cell cytokine expression (IL-4, IFN-γ), percentage in peripheral blood mononuclear cells of CD3+/CD4+/CD25hi+/FoxP3+ cells, and percentage of Treg that were FoxP3+ were evaluated using flow cytometry. Tumor measurements were performed after 2 cycles of therapy. Correlations between immune parameters and TS were assessed with Spearman rank correlations. Results: Ten pts were evaluable for Th1/Th2 responses; 9 for Treg. At baseline 7/10 had Th2 bias and 3/10 had Th1 bias. On day 28, pts maintained Th1 bias (n=3), switched to Th1 bias (n=3), or had decrease in magnitude of Th2 response (n=4). Additionally, a median 74.5% decrease occurred after 28 days of sunitinib in the percentage of CD3/CD4/CD25hi+/FoxP3+ in peripheral blood mononuclear cells, with a median 68.0% decrease of FoxP3+ Treg (CD3/CD4/CD25hi+) cells. Decrease in number of Treg correlated with relative change in Th1 response and Th2 bias (p<.05 for all correlations). All pts had TS including 2 pts with partial response. Degree of TS correlated with relative change in Th1 response (p=.03), and Th2 bias (p=.06), as well as the relative change in FoxP3+ Treg (p=.06). Conclusions: Our results suggest that sunitinib promotes an immunostimulatory Th1 bias and reduces Treg. This immunostimulatory mechanism may contribute to the anti-tumor effect in mRCC. Further studies are on-going. [Table: see text]
Collapse
|
159
|
Tamaskar I, Shaheen P, Wood L, Hodnick S, Nemec C, Garcia J, Dreicer R, Rini B, Bukowski R. Antitumor effects of sorafenib and sunitinib in patients (pts) with metastatic renal cell carcinoma (mRCC) who had prior therapy with anti-angiogenic agents. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.4597] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
4597 Background: Sorafenib and sunitinib are multi-targeted kinase inhibitors (TKI’s) with clinical activity in mRCC. Their effect in mRCC pts refractory to prior anti-angiogenic agents is unclear. We investigated the anti-tumor effect of sorafenib and sunitinib in patients with mRCC who failed prior treatment with anti-angiogenic agents. Methods: Pts with mRCC receiving sorafenib and sunitinib on compassionate use trials were identified. Those pts who had received prior treatment with anti-angiogenic agents defined as thalidomide, lenalidomide, M200 (anti-α5β1 integrin monoclonal antibody), bevacizumab, AG013736, sunitinib or sorafenib were selected and their treatment response to current sorafenib or sunitinib evaluated. Results: Seventy-two pts (39 receiving sorafenib and 33 receiving sunitinib) were identified. Of these 72 pts, 23 pts (32%) had received prior anti-angiogenic therapy as defined above. Demographics included: 19 male and 4 female, median age 61 years (range 44 to 77). Thirteen pts (57%) are currently evaluable; the remainder are too early for assessment. Twelve pts (92%) demonstrated tumor reduction including 4 pts with objective partial response (PR); 8 pts had stable disease with tumor shrinkage ranging from 4 to 27% and 1 pt had disease progression. Of the 4 PR pts, prior therapy included M200 (1 pt), lenalidomide (2 pts) and sorafenib (1 pt). Of the 13 evaluable pts 4 had failed a prior TKI and received a subsequent TKI and all had evidence of tumor shrinkage to subsequent therapy (sunitinib followed by sorafenib, 1pt - 16% shrinkage, sorafenib followed by sunitinib 2 pts - 33.4% and 24% and AG013736 followed by sunitinib 1 pt - 12% ). Conclusion: Sorafenib and sunitinib have anti-tumor activity in mRCC pts who have received prior anti-angiogenic agents. [Table: see text]
Collapse
|
160
|
Peat G, Thomas E, Duncan R, Wood L, Hay E, Croft P. Clinical classification criteria for knee osteoarthritis: performance in the general population and primary care. Ann Rheum Dis 2006; 65:1363-7. [PMID: 16627539 PMCID: PMC1798313 DOI: 10.1136/ard.2006.051482] [Citation(s) in RCA: 120] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Doubts have been expressed about the performance of the American College of Rheumatology (ACR) clinical classification criteria for osteoarthritis when applied in the general population. OBJECTIVE To investigate whether the distribution of population subgroups and underlying disease severity might explain the performance of these criteria in the population setting. METHODS Population-based cross-sectional study. 819 adults aged > or = 50 years reporting knee pain in the last 12 months were clinically assessed by research therapists using standardised protocols and blinded to radiographic status. All participants underwent plain radiography of the knees, scored by a single reader blinded to clinical status. The relationship between fulfilling the ACR clinical classification criteria for knee osteoarthritis and the presence of symptomatic radiographic knee osteoarthritis was summarised for the sample as a whole and within subgroups. RESULTS Radiographic osteoarthritis was present in 539 participants (68%) and symptomatic radiographic knee osteoarthritis in 259 (33%). 238 participants (30%) fulfilled the ACR clinical criteria for knee osteoarthritis. Agreement between the ACR clinical criteria and symptomatic radiographic knee osteoarthritis was low (sensitivity 41%; specificity 75%; positive predictive value 44%; negative predictive value 72%). Sensitivity and specificity did not vary markedly between population subgroups, although they were influenced by the underlying severity of radiographic osteoarthritis. CONCLUSION The ACR clinical criteria seem to reflect later signs in advanced disease. Other approaches may be needed to identify early, mild osteoarthritis in the general population and primary care.
Collapse
|
161
|
Shaheen PE, Vaziri SA, Ganapathi R, Elson P, Zhou M, Wood L, Bukowski RM. VHL gene mutation and hypermethylation in patients with renal cell carcinoma: Preliminary results and clinical correlation. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9619] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
162
|
Suppiah R, Budd GT, Wood L, Elson P. Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.9060] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
163
|
Mita CA, Schwartz G, Mita MM, Papadopoulos K, Wood L, de Jonge M, Yancik S, Hamilton M, Santabarbara P, Rowinsky E. A pilot, pharmacokinetic (PK), and pharmacodynamic (PD) study to determine the feasibility of intrapatient dose escalation to tolerable rash and the activity of maximal doses of erlotinib (E) in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.3045] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
164
|
Younis T, Skedgel C, Sellon M, Wood L, Davis M, Morzycki W, Virik K. Economic evaluation of two adjuvant chemotherapy regimens in lung cancer: Vinorelbine and cisplatin versus paclitaxel and carboplatin. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.6076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
165
|
Wood L, Leese MP, Mouzakiti A, Purohit A, Potter BVL, Reed MJ, Packham G. 2-MeOE2bisMATE induces caspase-dependent apoptosis in CAL51 breast cancer cells and overcomes resistance to TRAIL via cooperative activation of caspases. Apoptosis 2005; 9:323-32. [PMID: 15258464 DOI: 10.1023/b:appt.0000025809.80684.bd] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
2-Methoxyoestradiol (2-MeOE2) is an endogenous oestrogen metabolite which inhibits tubulin polymerisation and has anti-tumour and anti-angiogenic activity. 2-MeOE2 induces apoptosis in a wide range of cancer cell types and has recently been demonstrated to cooperate with TRAIL to induce apoptosis in breast cancer cells. 2-Methoxyoestradiol-3,17-bis-O,O-sulphamate (2-MeOE2bisMATE) is a sulfamoylated derivative of 2-MeOE2 with enhanced activity and improved pharmacokinetic properties, and 2-MeOE2bisMATE is a promising candidate for early clinical trials. It is important, therefore, to understand the mechanisms by which 2-MeOE2bisMATE acts, and whether it retains the ability to cooperate with TRAIL. We demonstrate that 2-MeOE2bisMATE-induced apoptosis of CAL51 breast cancer cells was associated with rapid activation of caspase 3 and 9, but not caspase 8 (as measured by BID cleavage) and was completely prevented by the caspase inhibitor zVADfmk. Interfering with Fas- or TRAIL-receptor function did not prevent 2-MeOE2bisMATE-induced apoptosis. Whereas CAL51 cells were resistant to TRAIL-induced apoptosis, 2-MeOE2bisMATE and TRAIL cooperated to induce cell death. This apoptosis was associated with enhanced activation of caspases, but not increased expression of the DR5 TRAIL receptor, previously demonstrated to be induced by 2-MeOE2. Therefore, 2-MeOE2bisMATE-induced apoptosis is dependent on caspases and like 2-MeOE2, 2-MeOE2bisMATE can overcome resistance to TRAIL by stimulating activation of downstream caspases. Our results suggest that 2-MeOE2bisMATE and TRAIL might be a particularly effective combination of anti-cancer agents.
Collapse
|
166
|
Taylor S, Bestall J, Cotter S, Falshaw M, Hood S, Parsons S, Wood L, Underwood M. Clinical service organisation for heart failure. Cochrane Database Syst Rev 2005:CD002752. [PMID: 15846638 PMCID: PMC4167847 DOI: 10.1002/14651858.cd002752.pub2] [Citation(s) in RCA: 32] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
BACKGROUND Chronic heart failure (CHF) is a serious, common condition associated with frequent hospitalisation. Several different disease management interventions (clinical service organisation interventions) for patients with CHF have been proposed. OBJECTIVES To assess the effectiveness of disease management interventions for patients with CHF. SEARCH STRATEGY We searched: Cochrane CENTRAL Register of Controlled Trials (to June 2003); MEDLINE (January 1966 to July 2003); EMBASE (January 1980 to July 2003); CINAHL (January 1982 to July 2003); AMED (January 1985 to July 2003); Science Citation Index Expanded (searched January 1981 to March 2001); SIGLE (January 1980 to July 2003); DARE (July 2003); National Research Register (July 2003); NHS Economic Evaluations Database (March 2001); reference lists of articles and asked experts in the field. SELECTION CRITERIA Randomised controlled trials comparing disease management interventions specifically directed at patients with CHF to usual care. DATA COLLECTION AND ANALYSIS At least two reviewers independently extracted data information and assessed study quality. Study authors were contacted for further information where necessary. MAIN RESULTS Sixteen trials involving 1,627 people were included. We classified the interventions into three models: multidisciplinary interventions (a holistic approach bridging the gap between hospital admission and discharge home delivered by a team); case management interventions (intense monitoring of patients following discharge often involving telephone follow up and home visits); and clinic interventions (follow up in a CHF clinic). There was considerable overlap within these categories, however the components, intensity and duration of the interventions varied. Case management interventions tended to be associated with reduced all cause mortality but these findings were not statistically significant (odds ratio 0.86, 95% confidence interval 0.67 to 1.10, P = 0.23), although the evidence was stronger when analysis was limited to the better quality studies (odds ratio 0.68, 95% confidence interval 0.46 to 0.98, P = 0.04). There was weak evidence that case management interventions may be associated with a reduction in admissions for heart failure. It is unclear what the effective components of the case management interventions are. The single RCT of a multidisciplinary intervention showed reduced heart-failure related re-admissions in the short term. At present there is little available evidence to support clinic based interventions. AUTHORS' CONCLUSIONS The data from this review are insufficient for forming recommendations. Further research should include adequately powered, multi-centre studies. Future studies should also investigate the effect of interventions on patients' and carers' quality of life, their satisfaction with the interventions and cost effectiveness.
Collapse
|
167
|
Jacobs P, Wood L. Biology and Management of Multiple Myeloma. Ann Oncol 2005. [DOI: 10.1093/annonc/mdi079] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
168
|
Whitty P, Eccles MP, Hawthorne G, Steen N, Vanoli A, Grimshaw JM, Wood L, Speed C, McDowell D. Improving services for people with diabetes: lessons from setting up the DREAM trial. ACTA ACUST UNITED AC 2005. [DOI: 10.1002/pdi.711] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
|
169
|
Beeram M, Rowinsky E, Patnaik A, Mita A, Forero L, Wood L, Tolcher A, Kamida M, De Jager R, Takimoto C. 514 Pharmacokinetic study of the distribution, metabolism and excretion of non-radiolabeled DX 8951f following repeated intravenous administration to patients with solid tumors. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80522-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
170
|
Holen KD, Syed S, Hannah AL, Binger K, Wood L, Zhou Y, Cropp GF, Johnson RG, Rowinsky E, Wilding G. Phase I study using continuous intravenous (CI) KOS-862 (Epothilone D) in patients with solid tumors. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2024] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
171
|
Masci P, Rybicki L, Tong K, Olencki T, Jacobs B, Wood L, Borden E. A Phase I evaluation of IFN α-1b in solid tumors, lymphoma or myeloma. J Clin Oncol 2004. [DOI: 10.1200/jco.2004.22.90140.2550] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
172
|
Carlton-Conway D, Tulloh R, Wood L, Kanabar D. Vitamin D deficiency and cardiac failure in infancy. J R Soc Med 2004. [PMID: 15121815 DOI: 10.1258/jrsm.97.5.238] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022] Open
|
173
|
Owen DJ, Wood L, Neilson JP. Antenatal care for women with multiple pregnancies: the Liverpool approach. Clin Obstet Gynecol 2004; 47:263-71. [PMID: 15024290 DOI: 10.1097/00003081-200403000-00026] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
174
|
Chung P, Ajitanand NN, Alexander JM, Anderson M, Best D, Brady FP, Case T, Caskey W, Cebra D, Chance JL, Cole B, Crowe K, Das AC, Draper JE, Gilkes ML, Gushue S, Heffner M, Hirsch AS, Hjort EL, Holzmann W, Huo L, Issah M, Justice M, Kaplan M, Keane D, Kintner JC, Klay J, Krofcheck D, Lacey RA, Lauret J, Lisa MA, Liu H, Liu YM, Milan J, McGrath R, Milosevich Z, Odyniec G, Olson DL, Panitkin S, Porile NT, Rai G, Ritter HG, Romero JL, Scharenberg R, Srivastava B, Stone NTB, Symons TJM, Taranenko A, Whitfield J, Wienold T, Witt R, Wood L, Zhang WN, Oeschler H. Near-threshold production of the multistrange Xi- hyperon. PHYSICAL REVIEW LETTERS 2003; 91:202301. [PMID: 14683356 DOI: 10.1103/physrevlett.91.202301] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/18/2003] [Indexed: 05/24/2023]
Abstract
The yield for the multistrange Xi(-) hyperon has been measured in 6A GeV Au+Au collisions via reconstruction of its decay products pi(-) and Lambda, the latter also being reconstructed from its daughter tracks of pi(-) and p. The measurement is rather close to the threshold for Xi(-) production and therefore provides an important test of model predictions. The measured yield for Xi(-) and Lambda are compared for several centralities. In central collisions the Xi(-) yield is found to be in excellent agreement with statistical and transport model predictions, suggesting that multistrange hadron production approaches chemical equilibrium in high baryon density nuclear matter.
Collapse
|
175
|
Chung P, Ajitanand NN, Alexander JM, Anderson M, Best D, Brady FP, Case T, Caskey W, Cebra D, Chance JL, Cole B, Crowe K, Das AC, Draper JE, Gilkes ML, Gushue S, Heffner M, Hirsch AS, Hjort EL, Holzmann W, Huo L, Issah M, Justice M, Kaplan M, Keane D, Kintner JC, Klay J, Krofcheck D, Lacey RA, Lauret J, Lisa MA, Liu H, Liu YM, McGrath R, Milosevich Z, Odyniec G, Olson DL, Panitkin S, Porile NT, Rai G, Ritter HG, Romero JL, Scharenberg R, Srivastava B, Stone NTB, Symons TJM, Taranenko A, Whitfield J, Witt R, Wood L, Zhang WN, Brown D, Pratt S, Wang F, Danielewicz P. Comparison of source images for protons, pi-'s, and lambda's in 6A GeV Au+Au collisions. PHYSICAL REVIEW LETTERS 2003; 91:162301. [PMID: 14611394 DOI: 10.1103/physrevlett.91.162301] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/28/2002] [Indexed: 05/24/2023]
Abstract
Source images are extracted from two-particle correlations constructed from strange and nonstrange hadrons produced in 6A GeV Au+Au collisions. Very different source images result from pp vs p Lambda vs pi(-)pi(-) correlations. Scaling by transverse mass can describe the apparent source size ratio for p/pi(-) but not for Lambda/pi(-) or Lambda/p. These observations suggest important differences in the space-time emission histories for protons, pions, and neutral strange baryons produced in the same events.
Collapse
|
176
|
|
177
|
Dewan N, Brabin B, Wood L, Dramond S, Cooper C. The effects of smoking on birthweight-for-gestational-age curves in teenage and adult primigravidae. Public Health 2003; 117:31-5. [PMID: 12802902 DOI: 10.1016/s0033-3506(02)00003-3] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]
Abstract
OBJECTIVE To compare the effect of smoking on the birthweight-for-gestational-age curves of teenage and adult primigravidae. METHODS A retrospective analysis of the perinatal database at the Liverpool Women's Hospital for the years 1997-1999 for teenage and adult primigravidae. RESULTS Records on 1157 primigravidae were available. There were no significant differences between the mean birthweight (3220 g +/- 666 vs 3244 g +/- 680, P = 0.43) and the proportion with low birthweight (LBW) babies (8.9% vs 10.6%, P = 0.39) between teenage and adult primigravidae, respectively. The percentage of women who smoked increased from the middle class (Townsend score -6- - 3) to the working class group (Townsend score +4- + 12) for both teenagers (33.3-51.3%) and adults (6.9-29.6%). The mean birthweight of babies of smoking mothers was significantly lower than for non-smoking mothers (3112 g +/- 639 vs 3327 g +/- 663, P = 0.00002). The birthweight-for-gestational-age pattern was lower at all gestational ages for smoking mothers in both the teenage and adult groups. Risk of LBW was significantly increased in teenagers who smoked (10.8% vs 3.9%, P < 0.01), but not in adult smokers. CONCLUSION Lower birthweights at all gestational ages were observed in babies of teenage and adult mothers who smoked.
Collapse
|
178
|
Groll AH, Wood L, Roden M, Mickiene D, Chiou CC, Townley E, Dad L, Piscitelli SC, Walsh TJ. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother 2002; 46:2554-63. [PMID: 12121932 PMCID: PMC127364 DOI: 10.1128/aac.46.8.2554-2563.2002] [Citation(s) in RCA: 102] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole (CD-ITRA) oral suspension were investigated in an open sequential dose escalation study with 26 human immunodeficiency virus (HIV)-infected children and adolescents (5 to 18 years old; mean CD4(+)-cell count, 128/microl) with oropharyngeal candidiasis (OPC). Patients received CD-ITRA at either 2.5 mg/kg of body weight once a day (QD) or 2.5 mg/kg twice a day (BID) for a total of 15 days. Pharmacokinetic sampling was performed after the first dose and for up to 120 h after the last dose, and antifungal efficacy was evaluated by standardized scoring of the oropharynx. Apart from mild to moderate gastrointestinal disturbances in three patients (11.5%), CD-ITRA was well tolerated. Two patients (7.6%) discontinued treatment prematurely due to study drug-related adverse events. After 15 days of treatment, the peak concentration of drug in plasma (C(max)), the area under the plasma concentration-time curve (AUC) from 0 to 24 h (AUC(0-24)), the concentration in plasma at the end of the dosing interval (predose) (C(min)), and the terminal half-life of itraconazole (ITRA) were (means and standard deviations) 0.604 +/- 0.53 microg/ml, 6.80 +/- 7.4 microg. h/ml, 0.192 +/- 0.06 microg/ml, and 56.48 +/- 44 h, respectively, for the QD regimen and 1.340 +/- 0.75 microg/ml, 23.04 +/- 14.5 microg. h/ml, 0.782 +/- 0.19 microg/ml, and 104.22 +/- 94 h, respectively, for the BID regimen. The mean AUC-based accumulation factors for ITRA on day 15 were 4.14 +/- 0.9 and 3.53 +/- 0.6, respectively. A comparison of the dose-normalized median AUC of the two dosage regimens revealed a trend toward nonlinear drug disposition (P = 0.05). The mean metabolic ratios (AUC of hydroxyitraconazole/AUC of ITRA) at day 15 were 1.96 +/- 0.1 for the QD regimen and 1.29 +/- 0.2 for the BID regimen, respectively (P < 0.05). The OPC score (range, 0 to 13) for all 26 patients decreased from a mean of 7.46 +/- 0.8 at baseline to 2.8 +/- 0.7 at the end of therapy (P < 0.001), demonstrating antifungal efficacy in this setting. The relationships among C(max), C(min), AUC(0-12), C(max)/MIC, C(min)/MIC, AUC(0-12)/MIC, time during the dosing interval when the plasma drug concentrations were above the MIC for the infecting isolate, and the residual OPC score at day 15 for the entire study population fit inhibitory effect pharmacodynamic models (r, 0.595 to 0.421; P, <0.01 to <0.05). All patients with fluconazole-resistant isolates responded to treatment with CD-ITRA; however, there was no clear correlation between the MIC of ITRA and response to therapy. In conclusion, CD-ITRA was well tolerated and efficacious for the treatment of OPC in HIV-infected pediatric patients. Pharmacodynamic modeling revealed significant correlations between plasma drug concentrations and antifungal efficacy. Based on this documented safety and efficacy, a dosage of 2.5 mg/kg BID can be recommended for the treatment of OPC in pediatric patients > or =5 years old.
Collapse
|
179
|
Grant S, McMillan K, Newell J, Wood L, Keatley S, Simpson D, Leslie K, Fairlie-Clark S. Reproducibility of the blood lactate threshold, 4 mmol.l(-1) marker, heart rate and ratings of perceived exertion during incremental treadmill exercise in humans. Eur J Appl Physiol 2002; 87:159-66. [PMID: 12070627 DOI: 10.1007/s00421-002-0608-2] [Citation(s) in RCA: 38] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/15/2002] [Indexed: 10/27/2022]
Abstract
The aim of this study was to investigate the reproducibility of blood lactate measurements, heart rate (HR) and ratings of perceived exertion (RPE) during treadmill exercise at speeds corresponding to the lactate threshold ( v(Th,la)-) and a fixed blood lactate concentration of 4 mmol.l(-1)( v(la)-(,4)). Possible differences in reproducibility related to fitness levels were also investigated. A group of 20 men [mean (SD)] [age 20.5 (1.4) years] and 16 women [age 21.2 (0.9) years] took part in the study. The subjects performed two identical incremental exercise tests consisting of at least six 4 min stages. Blood lactate concentrations, HR and RPE were recorded at the end of each stage. Limits of agreement (LoA), correlation coefficients and 95% confidence intervals for the mean difference between tests were employed to investigate the level of agreement and reproducibility of blood lactate concentration, HR and RPE. For the group as a whole, the sample correlation coefficient for speed at v(Th,la)- was r=0.88, and was r=0.92 for the speed at v(la)-(,4). At v(Th,la) -, the correlation coefficients for the moderately fit and unfit were r=0.94 and r=0.36, respectively, and at v(la)-(,4) r=0.93 and r=0.68, respectively. The LoA for the moderately fit group indicated that a change of 1.62 km.h(-1) in v(Th,la)- would be necessary to be considered a change in training status. For HR and RPE, relationships between the tests were generally poor. The LoA suggested that changes in scores must be unacceptably large. These findings cast doubt on the sensitivity of testing for change of blood lactate concentration, HR and RPE in this population.
Collapse
|
180
|
Kirschbaum N, Wood L, Lachenbruch P, Weinstein M, Daas A, Rautmann G, Spieser JM, Buchheit KH. Calibration of the Ph. Eur. BRP Batch 3/Mega 2 (US/FDA) standard for human coagulation factor VIII concentrate for use in the potency assay. PHARMEUROPA. SPECIAL ISSUE BIOLOGICALS 2002; 2002:31-64. [PMID: 12448031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
Abstract
The European Pharmacopoeia Biological Reference Preparation Batch 3/Mega 2 (United States/Food and Drug Administration) (Ph. Eur. BRP Batch 3/Mega 2 (US/FDA)) was developed as an internationally available, common working standard to replace the dwindling stocks of Mega 1 (the current US standard) and Ph. Eur. BRP Batch 2 (the current European standard). The potency was assigned in an international collaborative study with reference to four currently established standards, Ph. Eur. BRP batch 2, WHO 5th and 6th International Standard and Mega 1. Thirty-eight laboratories participated in the collaborative study. Each laboratory was asked to perform four independent assays. Participants used either the one stage clotting assay or the chromogenic assay or both. This publication reports the results obtained with both assays. The summary and conclusion, however highlight the results mainly with respect to the chromogenic assay, which is the assay prescribed in the European Pharmacopoeia. Data were analysed for both assays separately. A consensus potency value was calculated as the unweighted average of mean potencies determined against the four standards. A potency of 8.6 IU/vial as determined in the chromogenic substrate method was assigned to the candidate standard. Inter-laboratory agreement as assessed by calculation of the geometric coefficient of variation was below 10% for mean potencies against all four calibrators for the chromogenic assay. Ph. Eur. BRP Batch 3/Mega 2 (US/FDA) is a freeze-dried, plasma derived, high-purity concentrate. The material was filled into approximately 100,000 vials and lyophilised to a final residual moisture of < or = 2%. Approximately 90,000 vials of the standard are available, equally shared between the two co-ordinating centers. Based on the stability studies, the predicted mean percentage loss per year at -20 degrees C is 0.000% and thus the candidate standard appears to be stable. The Ph. Eur. BRP batch 3 was adopted by the European Pharmacopoeia Commission in November 2001.
Collapse
|
181
|
Klay JL, Ajitanand NN, Alexander JM, Anderson MG, Best D, Brady FP, Case T, Caskey W, Cebra D, Chance JL, Chung P, Cole B, Crowe K, Das AC, Draper JE, Gilkes ML, Gushue S, Heffner M, Hirsch AS, Hjort EL, Huo L, Justice M, Kaplan M, Keane D, Kintner JC, Krofcheck D, Lacey RA, Lauret J, Law C, Lisa MA, Liu H, Liu YM, McGrath R, Milosevich Z, Odyniec G, Olson DL, Panitkin SY, Pinkenburg C, Porile NT, Rai G, Ritter HG, Romero JL, Scharenberg R, Schroeder L, Srivastava B, Stone NTB, Symons TJM, Wang S, Wells R, Whitfield J, Wienold T, Witt R, Wood L, Zhang WN. Longitudinal flow of protons from (2-8)A GeV central Au+Au collisions. PHYSICAL REVIEW LETTERS 2002; 88:102301. [PMID: 11909348 DOI: 10.1103/physrevlett.88.102301] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/09/2001] [Indexed: 05/23/2023]
Abstract
Rapidity distributions of protons from central 197Au+197Au collisions measured by the E895 Collaboration in the energy range from (2-8)A GeV at the Brookhaven AGS are presented. Longitudinal flow parameters derived using a thermal model including collective longitudinal expansion are extracted from these distributions. The results show an approximately linear increase in the longitudinal flow velocity, <betagamma>(L), as a function of the logarithm of beam energy.
Collapse
|
182
|
Dewan N, Wood L, Maxwell S, Cooper C, Brabin B. Breast-feeding knowledge and attitudes of teenage mothers in Liverpool. J Hum Nutr Diet 2002; 15:33-7. [PMID: 11903787 DOI: 10.1046/j.1365-277x.2002.00332.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
OBJECTIVES To determine the knowledge and attitudes of teenage mothers towards breast-feeding. DESIGN A questionnaire of teenage (< 20 years) and non-teenage (> or = 20 years) primigravidae attending the antenatal care services at the Liverpool Women's Hospital, during the period April-May 2000. RESULTS Forty teenage primigravidae and 40 non-teenage primigravidae registered for the survey. Teenagers had poorer knowledge about breast-feeding than the non-teenagers, and fewer teenagers considered breast milk the best food for their baby. More teenagers than non-teenagers planned to bottle feed [23 (57.5%) vs. 9 (22.5%), P=0.002]. Only one teenager had knowledge about colostrum. Teenagers were more often single, had a lower level of education, higher unemployment, higher smoking frequency and less contact with a person who had previously breast-fed. CONCLUSION Teenage primigravidae have poor knowledge regarding breast-feeding compared with non-teenage primigravidae. A greater proportion of teenagers opted not to breast-feed compared with non-teenagers. Health education classes stressing the importance of breast-feeding should be emphasized in antenatal teenage clinics. More research is needed to understand how to improve the knowledge and motivation of adolescent girls to breast feed.
Collapse
|
183
|
Panitkin SY, Ajitanand NN, Alexander J, Anderson M, Best D, Brady FP, Case T, Caskey W, Cebra D, Chance J, Chung P, Cole B, Crowe K, Das A, Draper J, Gilkes M, Gushue S, Heffner M, Hirsch A, Hjort E, Huo L, Justice M, Kaplan M, Keane D, Kintner J, Klay J, Krofcheck D, Lacey R, Lauret J, Lisa MA, Liu H, Liu YM, McGrath R, Milosevich Z, Odyniec G, Olson D, Pinkenburg C, Porile N, Rai G, Ritter HG, Romero J, Scharenberg R, Schroeder LS, Srivastava B, Stone NT, Symons TJ, Wang S, Wells R, Whitfield J, Wienold T, Witt R, Wood L, Yang X, Zhang WN, Zhang Y, Brown DA, Danielewicz P. Model-independent source imaging using two-pion correlations in (2 to 8)a GeV Au+Au collisions. PHYSICAL REVIEW LETTERS 2001; 87:112304. [PMID: 11531518 DOI: 10.1103/physrevlett.87.112304] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/09/2000] [Indexed: 05/23/2023]
Abstract
We report a particle source imaging analysis based on two-pion correlations in high multiplicity Au+Au collisions at beam energies between 2A and 8A GeV. We apply the imaging technique introduced by Brown and Danielewicz, which allows a model-independent extraction of source functions with useful accuracy out to relative pion separations of about 20 fm. The extracted source functions have Gaussian shapes. Values of source functions at zero separation are almost constant across the energy range under study. Imaging results are found to be consistent with conventional source parameters obtained from a multidimensional Hanburg-Brown-Twiss analysis.
Collapse
|
184
|
Heibert SW, Lutterbach B, Durst K, Wang L, Linggi B, Wu S, Wood L, Amann J, King D, Hou Y. Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins. Cancer Chemother Pharmacol 2001; 48 Suppl 1:S31-4. [PMID: 11587363 DOI: 10.1007/s002800100302] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
AML-1 is one of the most frequently translocated genes in human leukemia. AML-1 binds DNA and activates or represses transcription, while the chromosomal translocation fusion proteins in acute myeloid leukemia subvert these functions. The t(8;21) is the second most frequent translocation in acute myeloid leukemia and creates a fusion between the DNA binding domain of AML-1 and the ETO (also known as MTG8) corepressor. The t(12;21) is found in up to 25% of pediatric B cell acute lymphoblastic leukemias and fuses the ETS family transcription factor TEL to the amino terminus of AML-1. In addition, the inv(16), the most frequent translocation in acute myeloid leukemia, fuses the AML-1 cofactor CBFbeta to the smooth muscle myosin heavy chain MYH11. Both the t(8;21) and t(12;21) create transcriptional repressors that impair AML-1 target gene expression. We demonstrated that the fusion proteins encoded by these translocations contact the nuclear hormone corepressors (N-CoR/SMRT), mSin3A, and histone deacetylases. We have also found that both TEL and AML-1 interact with mSin3A. TEL also binds N-CoR and histone deacetylase-3, indicating that wild-type TEL is a transcriptional repressor. The t(12;21) fuses the mSin3A interaction domain of TEL to AML-1 to transform AML-1 from a regulated to an unregulated transcriptional repressor. The recognition that AML-1 interacts with mSin3A to repress transcription suggested that the inv(16) fusion protein might also repress the transcription of AML-1-target genes. In fact, the inv(16) encodes a protein that cooperates with AML-1 to repress transcription. The inv(16) fusion protein was found in a ternary complex with AML-1 and mSin3A, suggesting that the inv(16) also acts by recruiting transcriptional corepressors and histone deacetylases.
Collapse
MESH Headings
- 3T3 Cells
- Animals
- COS Cells
- Chromosome Inversion
- Chromosomes, Human, Pair 12
- Chromosomes, Human, Pair 16
- Chromosomes, Human, Pair 18
- Chromosomes, Human, Pair 21
- Core Binding Factor Alpha 2 Subunit
- Humans
- Mice
- Nuclear Proteins/metabolism
- Nuclear Receptor Co-Repressor 1
- Oncogene Proteins, Fusion/genetics
- Oncogene Proteins, Fusion/metabolism
- Oncogene Proteins, Fusion/physiology
- RUNX1 Translocation Partner 1 Protein
- Repressor Proteins/genetics
- Repressor Proteins/metabolism
- Repressor Proteins/physiology
- Transcription Factors/genetics
- Transcription Factors/metabolism
- Transcription Factors/physiology
- Transcription, Genetic/physiology
- Translocation, Genetic
Collapse
|
185
|
Wood L, Coulson R. Revitalizing the General Practice Research Database: plans, challenges, and opportunities. Pharmacoepidemiol Drug Saf 2001; 10:379-83. [PMID: 11802580 DOI: 10.1002/pds.608] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
The General Practice Research Database (GPRD) is the world's largest computerized database of anonymized longitudinal patient records from general practice and is a unique public health research tool. Several issues have threatened the viability of the database in recent years; in April 1999 responsibility for its management and financial control was transferred to the UK Medicines Control Agency (MCA). This presentation outlines the MCA's plans and future vision for the GPRD.
Collapse
|
186
|
Wood L, Leese MR, Leblond B, Woo LW, Ganeshapillai D, Purohit A, Reed MJ, Potter BV, Packham G. Inhibition of superoxide dismutase by 2-methoxyoestradiol analogues and oestrogen derivatives: structure-activity relationships. ANTI-CANCER DRUG DESIGN 2001; 16:209-15. [PMID: 12049479] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Superoxide dismutases catalyse the dismutation of highly reactive superoxide ions to produce hydrogen peroxide and several lines of evidence suggest that these enzymes play important roles in the development and response to treatment of human cancers. For example, Mn-containing superoxide dismutase is frequently overexpressed in various cancer types and can contribute to resistance to apoptosis. 2-Methoxyoestradiol is a naturally occurring metabolic product of 17beta-oestradiol that inhibits tubulin polymerization and possesses growth inhibitory and cytotoxic activity in vitro and in vivo. More recently 2-methoxyoestradiol has also been shown to inhibit superoxide dismutase (SOD) in a tetrazolium salt based enzyme assay, suggesting that oestrogen derivatives might be useful starting points for the development of effective, non-toxic enzyme inhibitors. Here we have tested the SOD inhibiting activity of a range of oestrogen derivatives to determine structural features important for enzyme inhibition.
Collapse
|
187
|
Abstract
This study investigated anecdotal reports of gait and balance abnormalities in subjects with Chronic Fatigue Syndrome (CFS) by examining the effects of a light exercise test on postural sway and various gait parameters. Tests were performed on 11 CFS patients and 11 age- and sex-matched sedentary controls. Results demonstrated that postural sway was not significantly different in both groups before or after the exercise test. There were, however, significant differences in gait parameters between the two groups confirming anecdotal evidence, but these differences were not exacerbated by the exercise test. Heart rate responses demonstrated that both groups were exercising at similar loads, although this was perceived to be higher by the CFS group.
Collapse
|
188
|
Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab 2001; 280:E745-51. [PMID: 11287357 DOI: 10.1152/ajpendo.2001.280.5.e745] [Citation(s) in RCA: 1189] [Impact Index Per Article: 51.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/27/2022]
Abstract
Adipose tissue expresses tumor necrosis factor (TNF) and interleukin (IL)-6, which may cause obesity-related insulin resistance. We measured TNF and IL-6 expression in the adipose tissue of 50 lean and obese subjects without diabetes. Insulin sensitivity (S(I)) was determined by an intravenous glucose tolerance test with minimal-model analysis. When lean [body mass index (BMI) <25 kg/m(2)] and obese (BMI 30-40 kg/m(2)) subjects were compared, there was a 7.5-fold increase in TNF secretion (P < 0.05) from adipose tissue, and the TNF secretion was inversely related to S(I) (r = -0.42, P < 0.02). IL-6 was abundantly expressed by adipose tissue. In contrast to TNF, plasma (rather than adipose) IL-6 demonstrated the strongest relationship with obesity and insulin resistance. Plasma IL-6 was significantly higher in obese subjects and demonstrated a highly significant inverse relationship with S(I) (r = -0.71, P < 0.001). To separate the effects of BMI from S(I), subjects who were discordant for S(I) were matched for BMI, age, and gender. By use of this approach, subjects with low S(I) demonstrated a 3.0-fold increased level of TNF secretion from adipose tissue and a 2.3-fold higher plasma IL-6 level (P < 0.05) compared with matched subjects with a high S(I). Plasma IL-6 was significantly associated with plasma nonesterified fatty acid levels (r = 0.49, P < 0.002). Thus the local expression of TNF and plasma IL-6 are higher in subjects with obesity-related insulin resistance.
Collapse
|
189
|
Olencki T, Peereboom D, Wood L, Budd GT, Novick A, Finke J, McLain D, Elson P, Bukowski RM. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma. J Cancer Res Clin Oncol 2001; 127:319-24. [PMID: 11355147 DOI: 10.1007/s004320000211] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
PURPOSE A phase I followed by a phase II trial utilizing rIL-2, IFN alpha, and 5-FU were conducted in patients with unresectable and/or metastatic renal cell carcinoma. METHODS Treatment consisted of: rIL-2 at 5.0 x 10(6) IU/m2 SQ on days 1-5 for 4 weeks, rHUIFN alpha-2a at 5.0 x 10(6) U/m2 SQ on days 1, 3, and 5 for 4 weeks, and 5-FU by IV bolus on days 1-5 during week 1. In the phase I study, patients were treated at varying doses of 5-FU: I-none, II-250 mg/m2, III-300, and IV 375. A phase II trial was then conducted utilizing the same schedule and maximum tolerated dose (MTD) for 5-FU. RESULTS Twenty patients were entered into the phase I trial. Dose-limiting toxicity included grade III nausea and vomiting, and one sudden cardiac death. The MTD for 5-FU was determined to be 300 mg/m2. In the phase II trial, a median of two cycles of therapy was administered to 25 evaluable patients. Toxicity was moderate and consisted primarily of fevers, chills, fatigue, nausea/vomiting, and anorexia. Grade IV thrombocytopenia, consistent with ITP, developed in one patient each on the phase I and phase II trial. Seven partial responses were seen among 25 patients treated in the phase II trial for a 28% (CI 12-49%) response rate. CONCLUSIONS The addition of 5-FU to rIL-2 and rHuIFN alpha-2a appears to increase the toxicity of this therapy. Randomized trials will be required to determine if efficacy is enhanced.
Collapse
|
190
|
Chung P, Ajitanand NN, Alexander JM, Anderson M, Best D, Brady FP, Case T, Caskey W, Cebra D, Chance JL, Cole B, Crowe K, Das A, Draper JE, Gilkes ML, Gushue S, Heffner M, Hirsch AS, Hjort EL, Huo L, Justice M, Kaplan M, Keane D, Kintner JC, Klay J, Krofcheck D, Lacey RA, Lauret J, Lisa MA, Liu H, Liu YM, McGrath R, Milosevich Z, Odyniec G, Olson DL, Panitkin SY, Pinkenburg C, Porile NT, Rai G, Ritter HG, Romero JL, Scharenberg R, Schroeder L, Srivastava B, Stone NT, Symons TJ, Wienold T, Witt R, Whitfield J, Wood L, Zhang WN. Directed flow of lambda hyperons in (2-6 )A GeV Au+Au collisions. PHYSICAL REVIEW LETTERS 2001; 86:2533-2536. [PMID: 11289973 DOI: 10.1103/physrevlett.86.2533] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/01/2000] [Indexed: 05/23/2023]
Abstract
Directed flow measurements for Lambda hyperons are presented and compared to those for protons produced in the same Au+Au collisions (2A, 4A, and 6A GeV; b<5-6 fm). The measurements indicate that Lambda hyperons flow consistently in the same direction but with smaller magnitudes. A strong positive flow [for Lambdas] has been predicted in calculations which include the influence of the Lambda-nucleon potential. The experimental flow ratio Lambda/p is in qualitative agreement with expectations (approximately 2/3) from the quark counting rule at 2A GeV but is found to decrease with increasing beam energy.
Collapse
|
191
|
Hanley K, Wood L, Ng DC, He SS, Lau P, Moser A, Elias PM, Bikle DD, Williams ML, Feingold KR. Cholesterol sulfate stimulates involucrin transcription in keratinocytes by increasing Fra-1, Fra-2, and Jun D. J Lipid Res 2001; 42:390-8. [PMID: 11254751] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023] Open
Abstract
Lipids that are synthesized de novo in the epidermis, including fatty acids, oxysterols, 1,25-dihydroxyvitamin D(3), and farnesol, can regulate the differentiation of normal human keratinocytes (NHK). Cholesterol sulfate (CS), an epidermal lipid that is produced in the upper nucleated layers of the epidermis coincident with terminal differentiation, has been shown to play a role in the regulation of the late stages of keratinocyte differentiation, including formation of the cornified envelope. In the present study, we determined i) whether CS regulates involucrin (INV), an early keratinocyte differentiation marker, and ii) the mechanism by which CS regulates differentiation. mRNA and protein levels of INV, a precursor protein of the cornified envelope, increased 2- to 3-fold in NHK incubated in the presence of CS. In contrast, cholesterol had no effect on INV protein or mRNA levels. Transcriptional regulation was assessed in NHK transfected with INV promoter-luciferase constructs. CS increased luciferase reporter activity approximately 2- to 3-fold in NHK transfected with a 3.7-kb INV promoter construct. Deletional analysis revealed a CS-responsive region of the INV promoter located between bp --2452 and --1880. A 5-base pair (bp) mutation of the AP-1 site (bp --2117 to --2111) within this responsive region abolished CS responsiveness, suggesting a role for the AP-1 complex in the regulation of INV transcription by CS. Electrophoretic mobility shift analysis demonstrated increased binding of nuclear extracts isolated from CS-treated NHK to AP-1 DNA as compared with vehicle-treated controls. Incubation of the nuclear extract with the appropriate antibodies showed that the AP-1 DNA-binding complex contained Fra-1, Fra-2, and Jun D. Western blots demonstrated that CS treatment increased the levels of Fra-1, Fra-2, and Jun D, and Northern analyses revealed that CS increased mRNA levels for these same AP-1 factors. These data indicate that CS, an endogenous lipid synthesized by keratinocytes, regulates the early stages of keratinocyte differentiation, and may do so through its ability to modulate levels of AP-1 proteins. -- Hanley, K., L. Wood, D. C. Ng, S. S. He, P. Lau, A. Moser, P. M. Elias, D. D. Bikle, M. L. Williams, and K. R. Feingold. Cholesterol sulfate stimulates involucrin transcription in keratinocytes by increasing Fra-1, Fra-2, and Jun D. J. Lipid Res. 2001. 42: 390--398.
Collapse
|
192
|
Ackermann KH, Adams N, Adler C, Ahammed Z, Ahmad S, Allgower C, Amsbaugh J, Anderson M, Anderssen E, Arnesen H, Arnold L, Averichev GS, Baldwin A, Balewski J, Barannikova O, Barnby LS, Baudot J, Beddo M, Bekele S, Belaga VV, Bellwied R, Bennett S, Bercovitz J, Berger J, Betts W, Bichsel H, Bieser F, Bland LC, Bloomer M, Blyth CO, Boehm J, Bonner BE, Bonnet D, Bossingham R, Botlo M, Boucham A, Bouillo N, Bouvier S, Bradley K, Brady FP, Braithwaite ES, Braithwaite W, Brandin A, Brown RL, Brugalette G, Byrd C, Caines H, Calderón de la Barca Sánchez M, Cardenas A, Carr L, Carroll J, Castillo J, Caylor B, Cebra D, Chatopadhyay S, Chen ML, Chen W, Chen Y, Chernenko SP, Cherney M, Chikanian A, Choi B, Chrin J, Christie W, Coffin JP, Conin L, Consiglio C, Cormier TM, Cramer JG, Crawford HJ, Danilov VI, Dayton D, DeMello M, Deng WS, Derevschikov AA, Dialinas M, Diaz H, DeYoung PA, Didenko L, Dimassimo D, Dioguardi J, Dominik W, Drancourt C, Draper JE, Dunin VB, Dunlop JC, Eckardt V, Edwards WR, Efimov LG, Eggert T, Emelianov V, Engelage J, Eppley G, Erazmus B, Etkin A, Fachini P, Feliciano C, Ferenc D, Ferguson MI, Fessler H, Finch E, Fine V, Fisyak Y, Flierl D, Flores I, Foley KJ, Fritz D, Gagunashvili N, Gans J, Gazdzicki M, Germain M, Geurts F, Ghazikhanian V, Gojak C, Grabski J, Grachov O, Grau M, Greiner D, Greiner L, Grigoriev V, Grosnick D, Gross J, Guilloux G, Gushin E, Hall J, Hallman TJ, Hardtke D, Harper G, Harris JW, He P, Heffner M, Heppelmann S, Herston T, Hill D, Hippolyte B, Hirsch A, Hjort E, Hoffmann GW, Horsley M, Howe M, Huang HZ, Humanic TJ, Hümmler H, Hunt W, Hunter J, Igo GJ, Ishihara A, Ivanshin YI, Jacobs P, Jacobs WW, Jacobson S, Jared R, Jensen P, Johnson I, Jones PG, Judd E, Kaneta M, Kaplan M, Keane D, Kenney VP, Khodinov A, Klay J, Klein SR, Klyachko A, Koehler G, Konstantinov AS, Kormilitsyne V, Kotchenda L, Kotov I, Kovalenko AD, Kramer M, Kravtsov P, Krueger K, Krupien T, Kuczewski P, Kuhn C, Kunde GJ, Kunz CL, Kutuev RK, Kuznetsov AA, Lakehal-Ayat L, Lamas-Valverde J, Lamont MA, Landgraf JM, Lange S, Lansdell CP, Lasiuk B, Laue F, Lebedev A, LeCompte T, Leonhardt WJ, Leontiev VM, Leszczynski P, LeVine MJ, Li Q, Li Q, Li Z, Liaw CJ, Lin J, Lindenbaum SJ, Lindenstruth V, Lindstrom PJ, Lisa MA, Liu H, Ljubicic T, Llope WJ, LoCurto G, Long H, Longacre RS, Lopez-Noriega M, Lopiano D, Love WA, Lutz JR, Lynn D, Madansky L, Maier R, Majka R, Maliszewski A, Margetis S, Marks K, Marstaller R, Martin L, Marx J, Matis HS, Matulenko YA, Matyushevski EA, McParland C, McShane TS, Meier J, Melnick Y, Meschanin A, Middlekamp P, Mikhalin N, Miller B, Milosevich Z, Minaev NG, Minor B, Mitchell J, Mogavero E, Moiseenko VA, Moltz D, Moore CF, Morozov V, Morse R, de Moura MM, Munhoz MG, Mutchler GS, Nelson JM, Nevski P, Ngo T, Nguyen M, Nguyen T, Nikitin VA, Nogach LV, Noggle T, Norman B, Nurushev SB, Nussbaum T, Nystrand J, Odyniec G, Ogawa A, Ogilvie CA, Olchanski K, Oldenburg M, Olson D, Ososkov GA, Ott G, Padrazo D, Paic G, Pandey SU, Panebratsev Y, Panitkin SY, Pavlinov AI, Pawlak T, Pentia M, Perevotchikov V, Peryt W, Petrov VA, Pinganaud W, Pirogov S, Platner E, Pluta J, Polk I, Porile N, Porter J, Poskanzer AM, Potrebenikova E, Prindle D, Pruneau C, Puskar-Pasewicz J, Rai G, Rasson J, Ravel O, Ray RL, Razin SV, Reichhold D, Reid J, Renfordt RE, Retiere F, Ridiger A, Riso J, Ritter HG, Roberts JB, Roehrich D, Rogachevski OV, Romero JL, Roy C, Russ D, Rykov V, Sakrejda I, Sanchez R, Sandler Z, Sandweiss J, Sappenfield P, Saulys AC, Savin I, Schambach J, Scharenberg RP, Scheblien J, Scheetz R, Schlueter R, Schmitz N, Schroeder LS, Schulz M, Schüttauf A, Sedlmeir J, Seger J, Seliverstov D, Seyboth J, Seyboth P, Seymour R, Shakaliev EI, Shestermanov KE, Shi Y, Shimanskii SS, Shuman D, Shvetcov VS, Skoro G, Smirnov N, Smykov LP, Snellings R, Solberg K, Sowinski J, Spinka HM, Srivastava B, Stephenson EJ, Stock R, Stolpovsky A, Stone N, Stone R, Strikhanov M, Stringfellow B, Stroebele H, Struck C, Suaide AA, Sugarbaker E, Suire C, Symons TJ, Takahashi J, Tang AH, Tarchini A, Tarzian J, Thomas JH, Tikhomirov V, Szanto De Toledo A, Tonse S, Trainor T, Trentalange S, Tokarev M, Tonjes MB, Trofimov V, Tsai O, Turner K, Ullrich T, Underwood DG, Vakula I, Van Buren G, VanderMolen AM, Vanyashin A, Vasilevski IM, Vasiliev AN, Vigdor SE, Visser G, Voloshin SA, Vu C, Wang F, Ward H, Weerasundara D, Weidenbach R, Wells R, Wells R, Wenaus T, Westfall GD, Whitfield JP, Whitten C, Wieman H, Willson R, Wilson K, Wirth J, Wisdom J, Wissink SW, Witt R, Wolf J, Wood L, Xu N, Xu Z, Yakutin AE, Yamamoto E, Yang J, Yepes P, Yokosawa A, Yurevich VI, Zanevski YV, Zhang J, Zhang WM, Zhu J, Zimmerman D, Zoulkarneev R, Zubarev AN. Elliptic flow in Au+Au collisions at square root(S)NN = 130 GeV. PHYSICAL REVIEW LETTERS 2001; 86:402-407. [PMID: 11177841 DOI: 10.1103/physrevlett.86.402] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/13/2000] [Indexed: 05/23/2023]
Abstract
Elliptic flow from nuclear collisions is a hadronic observable sensitive to the early stages of system evolution. We report first results on elliptic flow of charged particles at midrapidity in Au+Au collisions at square root(S)NN = 130 GeV using the STAR Time Projection Chamber at the Relativistic Heavy Ion Collider. The elliptic flow signal, v2, averaged over transverse momentum, reaches values of about 6% for relatively peripheral collisions and decreases for the more central collisions. This can be interpreted as the observation of a higher degree of thermalization than at lower collision energies. Pseudorapidity and transverse momentum dependence of elliptic flow are also presented.
Collapse
|
193
|
Wood L. Innovative antineoplastic agents. JOURNAL OF INTRAVENOUS NURSING : THE OFFICIAL PUBLICATION OF THE INTRAVENOUS NURSES SOCIETY 2001; 24:48-55. [PMID: 11836844] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/23/2023]
Abstract
Cancer treatment options are changing as a result of extensive research efforts. New drugs and drug combinations proceed through specific phases of clinical research leading to possible Food and Drug Administration review and approval. Phase I, II, III, and IV clinical trials have detailed enrollment criteria and treatment plans designed to determine research objectives. These objectives can include reduction of toxicity, increased efficacy, and improved quality of life. Liposomal drug formulations, monoclonal antibody therapies, and cytoprotective agents are some of the new treatment approaches that have shown promise in clinical trials. This article reviews the clinical trial process, several innovative therapies, and the nursing responsibilities associated with caring for the patient with cancer.
Collapse
|
194
|
Trigwell S, Wood L, Jones P. Soluble urokinase receptor promotes cell adhesion and requires tyrosine-92 for activation of p56/59(hck). Biochem Biophys Res Commun 2000; 278:440-6. [PMID: 11097855 DOI: 10.1006/bbrc.2000.3818] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
The urokinase plasminogen activator receptor (uPAR) plays an important role in the migration of leukocytes. It occurs as a membrane-bound form that contains a glycosylphosphatidylinositol (GPI) anchor and also as a soluble form (suPAR) that lacks the GPI anchor. Recently, a sequence of amino acids, SRSRYLE, within the receptor has been found to become unmasked on uPA binding or chymotrypsin cleavage. Exposure of the epitope results in the activation of p56/p59(hck) kinase and chemotaxis of myelomonocytic cells. Using an epitope-tagged suPAR molecule, we found that both three-domain and two-domain suPAR promote the adhesion of differentiated THP-1 cells to fibronectin and vitronectin, indicating that suPAR can modify cell adhesion as well as cell migration. In addition, we found that the amino acid sequence RYLE, within the chemotactic peptide, is conserved across species and that alanine substitution of Tyr 92 decreased the ability of the peptide to activate p56/59(hck).
Collapse
|
195
|
MacCarthy-Morrogh L, Wood L, Brimmell M, Johnson PW, Packham G. Identification of a novel human BCL-X promoter and exon. Oncogene 2000; 19:5534-8. [PMID: 11114731 DOI: 10.1038/sj.onc.1203949] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BCL-XL is a key anti-apoptotic BCL-2 family protein that is widely expressed in human cancer cells and is induced in response to diverse survival signals. The translation initiation codon for BCL-XL is located in BCL-X exon II and previous analyses have indicated that BCL-XL RNAs initiate close to the start of exon II or additionally contain a non-coding first exon (exon IA) spliced to exon II. Using 5' RACE we have now identified a novel BCL-X non-coding exon (exon IB) which is spliced directly to exon II in place of exon IA. Exon IB-containing RNAs encoded BCL-XL and were detected in non-malignant lymphocytes and lymphoma cells from lymph node biopsies and were expressed at significant levels in cell lines derived from ovarian, colon and breast cancers. We identified two TATA-box sequences upstream of exon IB and demonstrated that surrounding genomic sequences contained strong promoter activity in lymphoma cells (approximately 300-fold active relative to controls). We have therefore identified a powerful new BCL-X promoter and a novel exon that contributes to BCL-XL expression.
Collapse
|
196
|
Adachi JA, Jiang Z, Cox M, Wood L, DuPont HL, Mathewson JJ. Serum antibody response induced in mice after oral administration of three different antigens of enterotoxigenic Escherichia coli in enteric coated microparticles. J Travel Med 2000; 7:304-8. [PMID: 11179951 DOI: 10.2310/7060.2000.00083] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
BACKGROUND Gastric digestion of these antigens plays an important role, decreasing the ability to deliver antigens to the gut-associated lymphoid tissue. To overcome this obstacle, microencapsulated antigens from enterotoxigenic Escherichia coli (ETEC) were evaluated for oral immunization of mice. METHODS Four groups of 10 each received 3 series of 3 doses each of (1) B subunit of cholera toxin (CTB), similar to heat-labile toxin of ETEC, (2) formalin-killed whole cell ETEC H10407 (FK-ETEC), (3) crude preparation of colonization factor antigen I (CFA/I), or (4) placebo. Serum antibody was measured on day 0 and 60 by ELISA. RESULTS In group 1 a CTB antibody response was induced in all mice, 3 with 1:105 titer and 7 with 1:106. These antibodies neutralized cholera toxin-induced steriodogenesis of Y-1 adrenal cells. In group 2, 8 mice developed a whole H10407 bacteria antibody titer of 1:100, one 1:200 and one showed no immune response. In the same group, an anti-CFA/I response was observed in 6 mice and anti-LPS in 4 mice as determined by Western blot. All mice in group 3 showed > 1:104 anti-CFA/I antibody titer. Group 4 mice did not develop an immune response to any ETEC antigens. CONCLUSIONS Microencapsulation appears to be a suitable approach for oral vaccination against ETEC and Vibrio cholerae.
Collapse
|
197
|
Taylor R, Davies R, Fox C, Sampson M, Weaver JU, Wood L. Appropriate insulin regimes for type 2 diabetes: a multicenter randomized crossover study. Diabetes Care 2000; 23:1612-8. [PMID: 11092282 DOI: 10.2337/diacare.23.11.1612] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/03/2023]
Abstract
OBJECTIVE To directly compare the rate of hypoglycemia and metabolic control achieved on once-daily ultralente insulin administration with twice-daily NPH insulin administration in patients with type 2 diabetes. Patient treatment satisfaction and quality of life were also examined before and during each treatment. RESEARCH DESIGN AND METHODS A crossover study was performed involving five centers and 79 patients with type 2 diabetes (fasting blood glucose > 8 mmol/l) with a 2-month run-in followed by two 6-month periods of either NPH or ultralente insulin administration. Patients were managed by a specialist nurse using a dosage adjustment protocol. RESULTS HbA1c was lower with NPH insulin therapy during each of the 6-month periods (9.7 +/- 0.2 vs. 9.1 +/- 0.3 and 9.8 +/- 0.2 vs. 9.0 +/- 0.3 mmol/l; both P < 0.01). The difference was accounted for by higher evening glucose levels with ultralente insulin (fasting 8.2 +/- 0.3 vs. 8.2 +/- 0.3 mmol/l, 6:00 P.M. 11.5 +/- 0.4 vs. 10.6 +/- 0.4 mmol/l). Despite worse control, the total number of hypoglycemic episodes was greater with ultralente insulin (220 vs. 171), and hypoglycemic episodes requiring third-party assistance occurred almost entirely with ultralente (14 vs. 1). Treatment satisfaction scores increased more with NPH insulin compared with ultralente and rose further upon changing to NPH insulin, but fell upon changing to ultralente insulin. These changes were highly significant (P < 0.001). Diabetes quality of life improved on both regimens. CONCLUSIONS These data clearly demonstrate the lower hypoglycemia rate, better glucose control, and greater treatment satisfaction accompanying therapy for type 2 diabetes with twice daily NPH compared with once daily ultralente insulin.
Collapse
|
198
|
Pelley R, Ganapathi R, Wood L, Rybicki L, McLain D, Budd GT, Peereboom D, Olencki T, Bukowski RM. A phase II pharmacodynamic study of pyrazoloacridine in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2000; 46:251-4. [PMID: 11021744 DOI: 10.1007/s002800000139] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
PURPOSE To perform a phase II trial of pyrazoloacridine (PZA), a novel DNA intercalator, in patients with metastatic colorectal carcinoma and no previous therapy. METHODS PZA was administered at a dose of 750 mg/m2 intravenously over 3 h every 21 days. Pharmacokinetic studies to determine PZA plasma concentrations were performed. RESULTS No responses were seen in 14 response-evaluable patients. Patients received a median of two cycles of PZA (range 1-6). Toxicity included neutropenia and neurologic side-effects, which were > or = grade III in 73% and 14%, respectively. High plasma concentrations of PZA (Cmax) correlated with low neutrophil counts (P = 0.04). CONCLUSIONS PZA is inactive at this dose and schedule in colorectal cancer, and produces moderately severe toxicity.
Collapse
|
199
|
|
200
|
Jacobs P, Wood L. Long-term survival in Waldenström's macroglobulinaemia. S Afr Med J 2000; 90:958, 960. [PMID: 11081091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/18/2023] Open
|